Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEland Oil & Gas Regulatory News (ELA)

  • There is currently no data for ELA

Opuama-3 Workover Update

25 Apr 2016 11:51

RNS Number : 2233W
Eland Oil & Gas PLC
25 April 2016
 

 

 

 

25 April 2016

 

Eland Oil & Gas PLC

 ("Eland" or the "Company")

 

Opuama-3 Workover Update

 

Eland Oil & Gas PLC (AIM: ELA), an oil & gas production and development company operating in West Africa, with an initial focus on Nigeria, is pleased to announce that, its joint-venture subsidiary Elcrest Exploration and Production Nigeria Ltd together with NPDC, its partner on OML 40, has completed the perforation of two new intervals in the Opuama-3 well and increased production from the two strings. Following the operational update on the Opuama-3 well re-entry announced on 14 April 2016 the following operation highlights have taken place on Opuama Field:

 

· Following the Production Logging Tool (PLT) runs in both strings of the Opuama 3 well the water ingress was identified to be coming from the lower D5000 producing interval. The D5000 reservoir was subsequently isolated by placing a cement plug across the interval with a coiled tubing intervention.

· Oriented perforations were shot into the D1000 upper reservoir in the Long String and into the D2000 reservoir in the Short String.

· Both strings were produced to a storage barge and flow rate tested.

· The Short String flowed for 6 hours on a 48/64" choke and produced 1,137 bbls of oil. This extrapolates to 4,548 barrels of dry crude per day.

· The Long String flowed for 1 hour on a 48/64" choke and produced 235 barrels of oil. This extrapolates to 5,640 barrels of dry crude per day.

· The successful cement job has removed over an estimated 1,000 barrels of water production from the well, significantly reducing the well's water cut.

· The combined flow from both strings was tested for 1 hour on 48/64" choke and produced 441 barrels of oil. This extrapolates to 10,584 barrels of dry crude per day from Opuama-3.

· Following the re-opening of the Forcados terminal, which we currently expect within a month, we then expect to recommence production from Opuama flowstation.

 

 

George Maxwell, CEO of Eland, commented:

 

"We are very pleased to announce the successful completion of the Opuama-3 re-entry and the strong results from flow testing the well. The results are beyond the high end of our previously announced expected range of 2,000-4,000 incremental gross barrels of oil produced per day. The two newly perforated reservoirs have proven to be highly productive. The initial combined flow rate from Opuama-3 well of 10,584 barrels of oil per day will move on normalised production, but will still be well in excess of our previous forecast.

 

Following this significant success we now move our focus to the Gbetiokun-1 workover well, also on licence OML 40. Our current plan is to commence operations on this high quality asset in the second half of the year, and we anticipate that a successful workover will lead to our current forecast of gross production in the range of 5,000-10,000 barrels of oil per day from the Gbetiokun-1 well"

 

 

 

For further information:

 

Eland Oil & Gas PLC (+44 (0)1224 737300)

www.elandoilandgas.com

George Maxwell, CEO

Louis Castro, CFO

Finlay Thomson, IR

 

Canaccord Genuity Limited (+44 (0)20 7 523 8000)

Henry Fitzgerald O'Connor

 Nilesh Patel

 

In accordance with the guidelines of the AIM Market of the London Stock Exchange, John Downey, a geologist and Eland's Chief Technical Officer, who has a BSc from Nottingham University, an MSc from Leeds University and has over 30 years of relevant experience in the upstream oil and gas industry and who is a member of the Society of Petroleum Engineers and meets the criteria of qualified person under the AIM guidance note for mining and oil and gas companies, has reviewed and approved the technical information contained in this announcement.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCSEAFSIFMSELL
Date   Source Headline
17th Jul 20095:57 pmBUSStudies Presented at International Conference on Alzheimer's Disease Reveal Substantial Economic Costs and Caregiver Burden Associated with Alzheimer's Disease
16th Jul 20092:18 pmRNSResults of Annual General Meeting
13th Jul 200911:30 amBUSElan and Transition Therapeutics Announce Phase 1 Data Showing ELND005 Achieves Desired Concentrations in Brain Tissue and Cerebrospinal Fluid
10th Jul 20094:59 pmRNSCancellation of UK Listing
8th Jul 20097:00 amBUSElan Announces Webcast of Second Quarter 2009 Financial Results
3rd Jul 200910:57 amRNSBlock Listing Six Monthly Return
2nd Jul 200912:57 pmRNSHolding in Company
2nd Jul 200912:41 pmPRNJohnson & Johnson, Elan Announce Definitive Agreement
1st Jun 20097:00 amBUSSubset Data from Two Randomized Phase 3 Trials Show TYSABRI® Significantly Improves Health-Related Quality of Life for Crohn's Disease Patients with Prior Exposure or Inadequate Response to Anti-TNF? Therapy
29th May 20094:36 pmRNSPrice Monitoring Extension
29th May 20092:00 pmBUSRenee P. Tannenbaum, Pharm.D. Joins Elan as Executive Vice President and Chief Commercial Officer
29th May 200911:54 amBUSTotal Voting Rights
30th Apr 200912:16 pmBUSTotal Voting Rights
27th Apr 20093:35 pmRNSAnnual Report
14th Apr 20095:09 pmRNSHolding(s) in Company
27th Feb 20092:44 pmBUSTotal Voting Rights
25th Feb 200912:23 pmBUSDirector/PDMR Shareholding
12th Feb 20096:00 pmBUSDirector/PDMR Shareholding
12th Feb 20096:00 pmBUSDirector/PDMR Shareholding
9th Feb 20097:00 amBUSMS Patients Treated with TYSABRI® Remain Free of Disease Activity for Two Years, According to Data Published in the Lancet Neurology
4th Feb 20092:32 pmRNSHolding(s) in Company
3rd Feb 20093:57 pmRNSHolding(s) in Company
30th Jan 20094:33 pmRNSHolding(s) in Company
28th Jan 20094:24 pmRNSHolding(s) in Company
13th Jan 20097:00 amBUSElan Clarifies Duration of Bapineuzumab Phase 3 Trials
12th Jan 20095:21 pmRNSHolding(s) in Company
12th Jan 20097:00 amBUSTysabri Update
2nd Jan 200912:21 pmRNSTotal Voting Rights
18th Dec 20084:24 pmRNSBlock Listing Six Monthly Return
16th Dec 200811:00 amBUSDirector Declaration
16th Dec 20087:00 amBUSElan to Present at the 27th Annual JP Morgan Healthcare Conference
15th Dec 20083:02 pmBUSTysabri Update
12th Dec 20087:00 amBUSElan Announces Resource Realignment
28th Nov 200810:47 amBUSTotal Voting Rights
25th Nov 20087:00 amBUSMary Stutts to Join Elan as Senior Vice President and Head of Corporate Relations
20th Nov 20087:00 amBUSCarlos V. Paya, MD, PhD, to Join Elan as Company President
3rd Nov 20085:12 pmRNSDirector/PDMR Shareholding
31st Oct 20084:11 pmRNSHolding in Company
31st Oct 200812:01 pmRNSTotal Voting Rights
30th Oct 20084:13 pmRNSTysabri Update
3rd Oct 20085:56 pmRNSHolding in Company
30th Sep 20084:11 pmRNSTotal Voting Rights
22nd Sep 200811:26 amRNSHolding In Company
22nd Sep 20087:00 amRNSTysabri Demonstrates Sustained Improvement
11th Sep 20087:39 amRNSDirector /PDMR Shareholding
1st Sep 20085:02 pmRNSHolding(s) in Company
29th Aug 200810:54 amRNSTotal Voting Rights
28th Aug 20087:00 amRNSInterim Results
14th Aug 20084:12 pmRNSHolding in Company
13th Aug 20085:22 pmRNSHolding in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.